Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672773 · ClinicalTrials.gov registry record · Phase 2
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Recurrent Extensive Stage Small Cell Lung Carcinoma and Refractory Extensive Stage Small Cell Lung Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 6
- Study locations
NCT03672773: Active Phase 2 study of Recurrent Extensive Stage Small Cell Lung Carcinoma and Refractory Extensive Stage Small Cell Lung Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
NCT03672773 is a Phase 2 study of Recurrent Extensive Stage Small Cell Lung Carcinoma and Refractory Extensive Stage Small Cell Lung Carcinoma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03672773, a Phase 2 study of Recurrent Extensive Stage Small Cell Lung Carcinoma and Refractory Extensive Stage Small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib and temozolomide may work better in treating participants with extensive-stage small cell lung cancer than either one alone.
Primary Outcome
Will be provided along with the corresponding exact 2-sided 95% confidence interval calculated using a method based on the F distribution.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Talazoparib
Study Locations (6)
California
- CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center - Bakersfield
- St. Joseph Heritage Healthcare - Fullerton
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Florida
- Orlando Health, Inc. d/b/a Orlando Health UF Health Center - Orlando
Indiana
- Ft. Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
Kansas
- Cancer Center of Kansas - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
What the registry record for NCT03672773 still lists
NCT03672773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Recurrent Extensive Stage Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT03672773 lists 6 locations in 4 states (California, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT03672773 about?
NCT03672773 is a clinical study titled "Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer". This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repai...
What is the current status of trial NCT03672773?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2018-10-31. Estimated completion is 2027-10-01.
What conditions does trial NCT03672773 study?
This clinical trial studies the following conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT03672773?
The interventions under investigation include: Temozolomide (DRUG), Talazoparib (DRUG).
Who is sponsoring clinical trial NCT03672773?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03672773 being conducted?
This trial has 6 study locations across California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03672773's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI